Selective Estrogen Receptor Modulators (SERMs): Mechanistic Insights Against Microbial Infections

Aakriti       Garg; Balraj       Singh; Ruchika       Sharma; Arti       Singh; Anoop       Kumar

doi:10.2174/1566524019666191014112133

Abstract

Background: Infections are one of the leading causes of death worldwide and currently available treatments remain unsatisfactory due to rise in the cases of antimicrobial resistance. Thus, there is a need for the development of new drugs with different mechanisms of action. However, the development of new antimicrobials agents is a long and expensive process. Hence, most of the pharmaceutical companies are looking forward to repurposing the already available drugs against microbial infections.

Methodology: The data related to SERMs and microbial infection has been extracted from Pub Med (from January 1997 to December 2018). A total of 101 studies have been published from 1997 -2018 regarding SERMs and microbial infections.

Results: On the basis of inclusion and exclusion criteria, 25 studies have been included for the analysis of level of evidence regarding antimicrobial effects of SERMs. Emerging reports have indicated the antimicrobial property of selective estrogen receptor modulators (SERMs) against normal and resistant strains under in vitro and in vivo conditions against wide variety of microorganisms through different mechanisms of action.

Conclusion: In conclusion, SERMs could be developed as a broad spectrum antimicrobial agent alone or in combination with existing antimicrobial agents.

Keywords: SERMs, drug repurposing, drug resistance, antimicrobial activity, microbial infections, estrogen.

[1] 
Rathi B, Latha N, Faletrov Y, Bhargava P, Shkumatov V. EDITORIAL: New avenues in controlling infectious diseases. Curr Top Med Chem  2017; 17(19): 2113.
[http://dx.doi.org/10.2174/156802661719170616164549] [PMID:  28664823] 
[2] 
Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed  2017; 7(5): 478-82.
[http://dx.doi.org/10.1016/j.apjtb.2017.01.019] 
[3] 
Sanders JW, Fuhrer GS, Johnson MD, Riddle MS. The epidemiological transition: the current status of infectious diseases in the developed world versus the developing world. Sci Prog  2008; 91(Pt 1): 1-37.
[http://dx.doi.org/10.3184/003685008X284628] [PMID:  18453281] 
[4] 
Ambrus JL Sr, Ambrus JL Jr. Nutrition and infectious diseases in developing countries and problems of acquired immunodeficiency syndrome. Exp Biol Med (Maywood)  2004; 229(6): 464-72.
[http://dx.doi.org/10.1177/153537020422900603] [PMID:  15169964] 
[5] 
De Lamballerie X, Colson P. The battle against infectious diseases in developing countries: the inseparable twins of diagnosis and therapy. Clin Chem  2006; 52(7): 1217-7.
[http://dx.doi.org/10.1373/clinchem.2006.071316] 
[6] 
Bhutta ZA, Salam RA, Das JK, Lassi ZS. Tackling the existing burden of infectious diseases in the developing world: existing gaps and the way forward. Infect Dis Poverty  2014; 3(1): 28.
[http://dx.doi.org/10.1186/2049-9957-3-28] [PMID:  25105015] 
[7] 
Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context  2018; 7: 212527
[http://dx.doi.org/10.7573/dic.212527] [PMID:  29872449] 
[8] 
Rayner C, Munckhof WJ. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern Med J  2005; 35(Suppl. 2): S3-S16.
[http://dx.doi.org/10.1111/j.1444-0903.2005.00976.x] [PMID:  16271060] 
[9] 
Rappuoli R, Bloom DE, Black S. Deploy vaccines to fight superbugs. Nature  2017; 14; 552(7684): 165-7.
[http://dx.doi.org/10.1038/d41586-017-08323-0] 
[10] 
World Health Organization (WHO); Antimicrobial resistance  Geneva, Switzerland: WHO.Available at: .. http://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance [accessed November 12, 2018].
[11] 
Rana R, Sharma R, Kumar A. Repurposing of existing statin drugs for treatment of microbial infections: how much promising? Infect Disord Drug Targets  2019; 19(3): 224-37.
[http://dx.doi.org/10.2174/1871526518666180806123230] [PMID:  30081793] 
[12] 
Corsello SM, Bittker JA, Liu Z, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med  2017; 23(4): 405-8.
[http://dx.doi.org/10.1038/nm.4306] [PMID:  28388612] 
[13] 
Kapoor Y, Sharma R, Kumar A. Repurposing of existing drugs for the bacterial infections: An In silico and In vitro study. Infect Disord Drug Targets 2018. Epub ahead of print
[http://dx.doi.org/10.2174/1871526519666181126094244] [PMID:  30474540] 
[14] 
Rana R, Sharma R, Kumar A. Repurposing of Fluvastatin against Candida albicans CYP450 lanosterol 14 α-demethylase, a target enzyme for antifungal therapy: An In silico and In vitro study. Curr Mol Med  2019; 19(7): 506-24.
[http://dx.doi.org/10.2174/1566524019666190520094644] [PMID:  31109273] 
[15] 
Gupta M, Sharma R, Kumar A. Comparative potential of Simvastatin, Rosuvastatin and Fluvastatin against bacterial infection: an in silico and in vitro study. Orient Pharm Exp Med  2019; 19: 259-75.
[http://dx.doi.org/10.1007/s13596-019-00359-z] 
[16] 
Xu B, Lovre D, Mauvais-Jarvis F. The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights. J Diabetes Complications  2017; 31(4): 773-9.
[http://dx.doi.org/10.1016/j.jdiacomp.2016.12.010] [PMID:  28185712] 
[17] 
Barreto GE, Santos-Galindo M, Garcia-Segura LM. Selective estrogen receptor modulators regulate reactive microglia after penetrating brain injury. Front Aging Neurosci  2014; 6: 132.
[http://dx.doi.org/10.3389/fnagi.2014.00132] [PMID:  24999330] 
[18] 
Christodoulakos GE, Lambrinoudaki IV, Botsis DC. The cardiovascular effects of selective estrogen receptor modulators. Ann N Y Acad Sci  2006; 1092(1): 374-84.
[http://dx.doi.org/10.1196/annals.1365.034] [PMID:  17308162] 
[19] 
Hussein MH, Schneider EK, Elliott AG, et al. From breast cancer to antimicrobial: combating extremely resistant Gram-negative “superbugs” using novel combinations of polymyxin B with selective estrogen receptor modulators. Microb Drug Resist  2017; 23(5): 640-50.
[http://dx.doi.org/10.1089/mdr.2016.0196] [PMID:  27935770] 
[20] 
Ho Sui SJ, Lo R, Fernandes AR, et al. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. Int J Antimicrob Agents  2012; 40(3): 246-51.
[http://dx.doi.org/10.1016/j.ijantimicag.2012.05.009] [PMID:  22819149] 
[21] 
Sun W, He S, Martínez-Romero C, et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res  2017; 137: 165-72.
[http://dx.doi.org/10.1016/j.antiviral.2016.11.017] [PMID:  27890675] 
[22] 
Gerits E, Defraine V, Vandamme K, et al. Repurposing toremifene for treatment of oral bacterial infections. Antimicrob Agents Chemother  2017; 61(3): e01846-16.
[http://dx.doi.org/10.1128/AAC.01846-16] [PMID:  27993858] 
[23] 
De Cremer K, Delattin N, De Brucker K, et al. Oral administration of the broad-spectrum antibiofilm compound toremifene inhibits Candida albicans and Staphylococcus aureus biofilm formation in vivo. Antimicrob Agents Chemother  2014; 58(12): 7606-10.
[http://dx.doi.org/10.1128/AAC.03869-14] [PMID:  25288093] 
[24] 
Doroodgar M, Delavari M, Doroodgar M, Abbasi A, Taherian AA, Doroodgar A. Tamoxifen induces apoptosis of Leishmania major promastigotes in vitro. Korean J Parasitol  2016; 54(1): 9-14.
[http://dx.doi.org/10.3347/kjp.2016.54.1.9] [PMID:  26951973] 
[25] 
Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med  2012; 125(1)(Suppl.): S3-S13.
[http://dx.doi.org/10.1016/j.amjmed.2011.11.001] [PMID:  22196207] 
[26] 
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P&T  2015; 40(4): 277-83.
[PMID:  25859123] 
[27] 
Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist  2017; 10: 237-45.
[http://dx.doi.org/10.2147/IDR.S118892] [PMID:  28814889] 
[28] 
Jiang YC, Feng H, Lin YC, Guo XR. New strategies against drug resistance to herpes simplex virus. Int J Oral Sci  2016; 8(1): 1-6.
[http://dx.doi.org/10.1038/ijos.2016.3] [PMID:  27025259] 
[29] 
Ouellette M. Biochemical and molecular mechanisms of drug resistance in parasites. Trop Med Int Health  2001; 6(11): 874-82.
[http://dx.doi.org/10.1046/j.1365-3156.2001.00777.x] [PMID:  11703841] 
[30] 
Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr  2016; 4(2): 10.
[PMID:  27227291] 
[31] 
Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta  2009; 1794(5): 808-16.
[http://dx.doi.org/10.1016/j.bbapap.2008.11.005] [PMID:  19100346] 
[32] 
Fernández L, Hancock RE. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev  2012; 25(4): 661-81.
[http://dx.doi.org/10.1128/CMR.00043-12] [PMID:  23034325] 
[33] 
Singh S, Singh SK, Chowdhury I, Singh R. Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents. Open Microbiol J  2017; 11: 53-62.
[http://dx.doi.org/10.2174/1874285801711010053] [PMID:  28553416] 
[34] 
Montealegre MC, Roh JH, Rae M, et al. Differential penicillin-binding protein 5 (PBP5) levels in the Enterococcus faecium clades with different levels of ampicillin resistance. Antimicrob Agents Chemother  2016; 61(1): e02034-16.
[PMID:  27821450] 
[35] 
Food and Drug Administration (FDA). Drugs@FDA: FDA Approved Drug Products. Available at: . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017970 [accessed December 10, 2018].
[36] 
electronic Medicines Compendium (eMC). Tamoxifen 20mg
Film-Coated Tablets. Available at:. . https://www.medicines.org.uk/emc/product/2248/smpc 20updated on 10 August 2018 [accessed November 15,
2018].18
[37] 
Food and Drug Administration (FDA). Drugs@FDA: FDA
Approved Drug Products. Available at:.. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020497 [accessed December 10, 2018].
[38] 
Food and Drug Administration (FDA). Drugs@FDA: FDA
Approved Drug Products. Available at:. . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020815  [accessed December 10, 2018]. 
[39] 
electronic Medicines Compendium (eMC). Fareston 60mg
Tablets. Available at:. . https://www.medicines.org.uk/emc/product/1705/smpc updated on 28 June 2017 [accessed December 11, 2018].
[40] 
electronic Medicines Compendium (eMC). Evista 60mg filmcoated
tablets. Available at:. . https://www.medicines.org.uk/emc/product/3778/smpc updated on 23 October 2017 [accessed December 11, 2018].
[41] 
Qin T, Yuan ZY, Peng RJ, et al. Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis. Curr Oncol  2013; 20(4): 196-204.
[http://dx.doi.org/10.3747/co.20.1231] [PMID:  23904760] 
[42] 
D’Amelio P, Isaia GC. The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother  2013; 14(7): 949-56.
[http://dx.doi.org/10.1517/14656566.2013.782002] [PMID:  23521229] 
[43] 
Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet  2003; 42(4): 361-72.
[http://dx.doi.org/10.2165/00003088-200342040-00004] [PMID:  12648026] 
[44] 
Farrar MC, Jacobs TF.  Tamoxifen.StatPearls. Treasure
 Island, FL: StatPearls Publishing 2019.https://www.ncbi.nlm.nih.gov/books/NBK532905/  Updated 2018 Dec 29 Internet
[45] 
 Toremifene-Indication, dosage, side effects, and precautions.
 Available at:. . https://www.medindia.net/doctors/drug_information/toremifene.htm  [accessed 23August 2019]. 
[46] 
 Who should not take raloxifene HCl? Available at:. . https://www.webmd.com/drugs/2/drug-5191/raloxifene-oral/details/list-contraindications [accessed on 23 August 2019]. 
[47] 
El Arbi M, Théolier J, Pigeon P, et al. Antibacterial properties and mode of action of new triaryl butene citrate compounds. Eur J Med Chem  2014; 76: 408-13.
[http://dx.doi.org/10.1016/j.ejmech.2014.02.037] [PMID:  24602786] 
[48] 
Jang WS, Kim S, Podder B, et al. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J Microbiol Biotechnol  2015; 25(6): 946-50.
[http://dx.doi.org/10.4014/jmb.1412.12023] [PMID:  25639719] 
[49] 
Tisi R, Rigamonti M, Groppi S, Belotti F. Calcium homeostasis and signaling in fungi and their relevance for pathogenicity of yeasts and filamentous fungi. AIMS Mol Sci  2016; 3(4): 505-49.
[http://dx.doi.org/10.3934/molsci.2016.4.505] 
[50] 
Reimão JQ, Miguel DC, Taniwaki NN, Trinconi CT, Yokoyama-Yasunaka JK, Uliana SR. Antileishmanial activity of the estrogen receptor modulator raloxifene. PLoS Negl Trop Dis  2014; 8: (5) e2842
[http://dx.doi.org/10.1371/journal.pntd.0002842] [PMID:  24810565] 
[51] 
Dittmar AJ, Drozda AA, Blader IJ. Drug repurposing screening identifies novel compounds that effectively inhibit Toxoplasma gondii growth. MSphere  2016; 1(2): e00042-15.
[http://dx.doi.org/10.1128/mSphere.00042-15] [PMID:  27303726] 
[52] 
Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med  2013; 5(190)190ra79
[http://dx.doi.org/10.1126/scitranslmed.3005471] [PMID:  23785035] 
[53] 
Zhao Y, Ren J, Harlos K, et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature  2016; 535(7610): 169-72.
[http://dx.doi.org/10.1038/nature18615] [PMID:  27362232] 
[54] 
Zheng K, Chen M, Xiang Y, et al. Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen and NPPB. Biochem Biophys Res Commun  2014; 446(4): 990-6.
[http://dx.doi.org/10.1016/j.bbrc.2014.03.050] [PMID:  24657267] 
[55] 
Kamboj A, Randhawa H. Pharmacological action and sar of thiophene derivatives: A review. J Pharm Res  2012; 5(5): 2676-82.
[56] 
Delattin N, De Brucker K, Vandamme K, et al. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J Antimicrob Chemother  2014; 69(4): 1035-44.
[http://dx.doi.org/10.1093/jac/dkt449] [PMID:  24284780] 
[57] 
Butts A, Koselny K, Chabrier-Roselló Y, et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. MBio  2014; 5(1): e00765-13.
[http://dx.doi.org/10.1128/mBio.00765-13] [PMID:  24520056] 
[58] 
Trinconi CT, Reimão JQ, Yokoyama-Yasunaka JK, Miguel DC, Uliana SR. Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis. Antimicrob Agents Chemother  2014; 58(5): 2608-13.
[http://dx.doi.org/10.1128/AAC.01315-13] [PMID:  24550333] 
[59] 
Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, Uliana SR. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother  2009; 63(2): 365-8.
[http://dx.doi.org/10.1093/jac/dkn509] [PMID:  19095684] 
[60] 
Eissa MM, Amer EI, El Sawy SM. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis. Exp Parasitol  2011; 128(4): 382-90.
[http://dx.doi.org/10.1016/j.exppara.2011.05.009] [PMID:  21620834] 
[61] 
Escobedo G, Palacios-Arreola MI, Olivos A, López-Griego L, Morales-Montor J. Tamoxifen treatment in hamsters induces protection during taeniosis by Taenia solium. Biomed Res Int  2012; 2013: 280496
[62] 
Cong Y, Hart BJ, Gross R, et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One  2018; 13(3)e0194868
[http://dx.doi.org/10.1371/journal.pone.0194868] [PMID:  29566060] 
[63] 
Wang LL, Chen Q, Zhou LN, Guo Y. [Study of gonadal
hormone drugs in blocking filovirus entry of cells in vitro]. Yao Xue Xue Bao. 2015; 50(12): 1545-50.
[PMID: 27169275] 
[64] 
Dyall J, Nelson EA, DeWald LE, et al. Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures J Infect Dis  2018; 25(suppl_5): S672-8.
[65] 
Furusyo N, Ogawa E, Sudoh M, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol  2012; 57(6): 1186-92.
[http://dx.doi.org/10.1016/j.jhep.2012.08.003] [PMID:  22889955] 
[66] 
Miguel DC, Yokoyama-Yasunaka JK, Uliana SR. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl Trop Dis  2008; 2(6)e249
[http://dx.doi.org/10.1371/journal.pntd.0000249] [PMID:  18545685] 
[67] 
Trinconi CT, Reimão JQ, Coelho AC, Uliana SR. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. J Antimicrob Chemother  2016; 71(5): 1314-22.
[http://dx.doi.org/10.1093/jac/dkv495] [PMID:  26851606] 
[68] 
Dolan K, Montgomery S, Buchheit B, Didone L, Wellington M, Krysan DJ. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob Agents Chemother  2009; 53(8): 3337-46.
[http://dx.doi.org/10.1128/AAC.01564-08] [PMID:  19487443] 

Rights & Permissions Print Cite

Article Metrics

16

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1566524019666191014112133	Print ISSN 1566-5240
Publisher Name Bentham Science Publisher	Online ISSN 1875-5666

Current Molecular Medicine

Selective Estrogen Receptor Modulators (SERMs): Mechanistic Insights Against Microbial Infections

Abstract Play Pause

Related Journals

Related Books

Abstract